Trials / Recruiting
RecruitingNCT05633810
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes (COLCOT-T2D)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 10,000 (estimated)
- Sponsor
- Montreal Heart Institute · Academic / Other
- Sex
- All
- Age
- 55 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin | 40 mg non-enteric-coated tablet taken twice daily. |
| DRUG | Aspirin Placebo | non-enteric-coated tablet taken twice daily. |
| DRUG | Colchicine | 0.5 mg tablet taken once daily |
| DRUG | Colchicine Placebo | tablet taken once daily. |
Timeline
- Start date
- 2022-12-21
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2022-12-01
- Last updated
- 2026-03-10
Locations
39 sites across 8 countries: Australia, Canada, Denmark, Finland, France, Greece, Italy, Portugal
Source: ClinicalTrials.gov record NCT05633810. Inclusion in this directory is not an endorsement.